MERCURY LABORATORIES
|
MERCURY LABORATORIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 46.49 | 29.68 | 44.48 | 26.90 | 23.63 |
| CEPS(Rs) | 67.18 | 50.12 | 60.48 | 42.48 | 37.20 |
| DPS(Rs) | 3.50 | 3.50 | 3.50 | 2.00 | 1.50 |
| Book NAV/Share(Rs) | 380.24 | 335.89 | 307.46 | 266.48 | 241.38 |
| Tax Rate(%) | 25.55 | 29.25 | 32.51 | 25.43 | 29.98 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.38 | 12.07 | 13.98 | 10.77 | 10.31 |
| EBIT Margin(%) | 10.43 | 9.46 | 12.46 | 8.99 | 9.26 |
| Pre Tax Margin(%) | 9.95 | 8.69 | 11.53 | 7.56 | 7.30 |
| PAT Margin (%) | 7.41 | 6.15 | 7.78 | 5.64 | 5.11 |
| Cash Profit Margin (%) | 10.70 | 10.38 | 10.58 | 8.90 | 8.04 |
| Performance Ratios | |||||
| ROA(%) | 8.58 | 5.57 | 8.77 | 5.68 | 5.20 |
| ROE(%) | 12.98 | 9.23 | 15.50 | 10.59 | 10.26 |
| ROCE(%) | 16.29 | 12.26 | 20.56 | 13.25 | 13.77 |
| Asset Turnover(x) | 1.16 | 0.91 | 1.13 | 1.01 | 1.02 |
| Sales/Fixed Asset(x) | 1.73 | 1.38 | 1.77 | 1.59 | 1.69 |
| Working Capital/Sales(x) | 2.98 | 2.97 | 3.62 | 3.48 | 3.71 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.58 | 0.73 | 0.57 | 0.63 | 0.59 |
| Receivable days | 92.32 | 123.77 | 108.21 | 119.27 | 111.78 |
| Inventory Days | 33.14 | 37.61 | 28.38 | 39.17 | 47.57 |
| Payable days | 128.23 | 225.52 | 178.16 | 210.82 | 199.88 |
| Valuation Parameters | |||||
| PER(x) | 12.59 | 16.34 | 14.45 | 10.45 | 14.34 |
| PCE(x) | 8.71 | 9.68 | 10.62 | 6.62 | 9.11 |
| Price/Book(x) | 1.54 | 1.44 | 2.09 | 1.05 | 1.40 |
| Yield(%) | 0.60 | 0.72 | 0.54 | 0.71 | 0.44 |
| EV/Net Sales(x) | 0.91 | 0.97 | 1.16 | 0.67 | 0.88 |
| EV/Core EBITDA(x) | 6.64 | 7.23 | 7.58 | 5.47 | 7.21 |
| EV/EBIT(x) | 8.69 | 10.29 | 9.28 | 7.46 | 9.49 |
| EV/CE(x) | 1.01 | 0.90 | 1.21 | 0.68 | 0.85 |
| M Cap / Sales | 0.93 | 1.00 | 1.12 | 0.59 | 0.73 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 30.06 | -15.56 | 19.79 | 3.15 | 7.04 |
| Core EBITDA Growth(%) | 31.82 | -25.45 | 49.26 | 3.68 | 39.88 |
| EBIT Growth(%) | 43.31 | -35.90 | 66.14 | 0.15 | 52.81 |
| PAT Growth(%) | 56.62 | -33.27 | 65.34 | 13.82 | 40.87 |
| EPS Growth(%) | 56.62 | -33.27 | 65.34 | 13.82 | 40.87 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.13 | 0.19 | 0.22 | 0.33 |
| Current Ratio(x) | 2.54 | 2.24 | 2.01 | 2.09 | 1.89 |
| Quick Ratio(x) | 2.12 | 1.81 | 1.73 | 1.73 | 1.48 |
| Interest Cover(x) | 21.70 | 12.28 | 13.33 | 6.30 | 4.72 |
| Total Debt/Mcap(x) | 0.08 | 0.09 | 0.09 | 0.21 | 0.23 |
Compare Financial Ratios of peers of MERCURY LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MERCURY LABORATORIES | ₹107.3 Cr | 2% | 1.7% | 37% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹360,920.0 Cr | -2.3% | -6.5% | 55.3% | Stock Analytics | |
| CIPLA | ₹113,794.0 Cr | 4.1% | -4.8% | 55.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹106,860.0 Cr | 7.8% | 17.4% | 20.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,316.0 Cr | 4% | 0.8% | 29.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,380.9 Cr | -1.2% | -5.2% | 83.9% | Stock Analytics | |
MERCURY LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MERCURY LABORATORIES | 2% |
1.7% |
37% |
| SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses
